Key highlights
- Overall response rate of 62.7% achieved among 51 response-evaluable patients
- Disease control rate reached 86.3% in a heavily pretreated patient population
- Median progression-free survival recorded at 6.0 months versus 3-4 months historically
- Two patients achieved complete responses and 30 patients showed partial responses
- Acceptable safety profile maintained with no evidence of unexpected hepatotoxicity
Clinical Trial Outcomes and Efficacy
Inhibrx Biosciences shared updated Phase 1/2 expansion study results for ozekibart (INBRX-109), a tetravalent death receptor 5 agonist. The study evaluated the candidate in combination with irinotecan and temozolomide for patients with relapsed or refractory Ewing sarcoma. As of the September 2026 data cutoff, 60 patients were treated, including nine adolescents. The combination showed significant efficacy, with 84.3% of evaluable patients experiencing a measurable reduction in tumor size. Notably, two patients achieved complete responses, and one patient has maintained a partial response for over two years, suggesting clinical durability in an aggressive disease setting.
Market Benchmarks and Regulatory Path
These clinical outcomes represent a substantial improvement over historical benchmarks for Ewing sarcoma treatment. Current standard regimens typically yield an overall response rate between 15% and 30%, whereas ozekibart reached 62.7%. The extension of median progression-free survival to 6.0 months from the historical average of 3 to 4 months highlights the potential for improved patient outcomes. Inhibrx intendeds to discuss these results with the FDA to advance the program. The agency has already accepted a biologics license application for ozekibart in conventional chondrosarcoma, indicating a broadening regulatory profile for the therapeutic candidate.
Strategic Commentary
“In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options.”
Business and Financial Profile
Inhibrx Biosciences is a clinical-stage biopharmaceutical firm utilizing a proprietary modular protein engineering platform to develop therapeutics for oncology and orphan diseases. Despite the positive clinical update, INBX shares have experienced a 18.13% decline over the past week, leaving the stock with a 14-day RSI of 38.2. The company maintains a market capitalization of approximately $1.1 billion. While quarterly revenue stands at $2.0 million, the focus remains on R&D investment. Moving ozekibart toward potential commercialization in the underserved Ewing sarcoma market, which affects roughly 2,500 individuals in the U.S., remains a central strategic objective.
Management commentary
“The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas.”
| Share price | $74.18 |
|---|---|
| Market cap | $1.1B |
| Revenue (annual) | $1M |
| 1-month price change | -17.42% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Inhibrx Biosciences announcing updated Phase 1/2 clinical data for ozekibart in Ewing sarcoma.
Track Inhibrx Biosciences, Inc. live
Get the next Inhibrx Biosciences, Inc. SEC filing seconds after it lands.